ZSP 0678
Alternative Names: ZSP-0678Latest Information Update: 16 Jun 2023
At a glance
- Originator Guangdong Raynovent Biotech
- Class Hepatoprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Biliary cirrhosis; Non-alcoholic steatohepatitis
Most Recent Events
- 15 Jun 2023 ZSP 0678 is still in phase I trials for Non-alcoholic steatohepatitis (In volunteers) in China (PO, Tablet) (Guangdong Raynovent Biotech pipeline, June 2023)
- 28 Dec 2022 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis(In volunteers) in China (PO, Tablet)
- 29 Nov 2022 Phase-I clinical trials in Biliary cirrhosis in China (PO) (Guangdong Raynovent Biotech pipeline; November 2022)